Search Results - "Bredius, R.G.M."

Primary immunodeficiencies in the Netherlands: National patient data demonstrate the increased risk of malignancy by Jonkman-Berk, B.M, van den Berg, J.M, ten Berge, I.J.M, Bredius, R.G.M, Driessen, G.J, Dalm, V.A.S.H, van Dissel, J.T, van Deuren, M, Ellerbroek, P.M, van der Flier, M, van Hagen, P.M, van Montfrans, J.M, Rutgers, A, Schölvinck, E.H, de Vries, E, van Beem, R.T, Kuijpers, T.W

“…Abstract Purpose To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for…”
Get full text

Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B by Schauwvlieghe, A.F.A.D., Bredius, R.G.M., Verdijk, R.M., Smiers, F.J.W., van der Beek, M.T., Goemans, B.F., Zwaan, C.M., Brüggemann, R.J., Rijnders, B.J.A.

“…•Azole-resistant aspergillosis is an emerging global problem.•CNS infections with azole-resistant Aspergillus have a dismal outcome.•Three patients were…”
Get full text

Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics by ten Brink, M.H., Zwaveling, J., Swen, J.J., Bredius, R.G.M., Lankester, A.C., Guchelaar, H.J.

“…•Optimal PK models of busulfan in pediatric patients incorporate growth and maturation processes.•PG markers should to be incorporated into PK models to…”
Get full text

Optimization of Anti-Thymocyte Globulin Exposure in Paediatric Bone Marrow Transplantation in Order to Design an individualized Dosing Regimen by Bartelink, I.H, Jol-van der Zijde, E.M, Boelens, J.J, Bredius, R.G.M, Egberts, A.C.G, Danhof, M, van Tol, M.J.D, Knibbe, C.A.J

Get full text

Optimizing the Busulfan Dosing Regimen to Get a More Predictable Exposure: A Data Driven Analysis by Bartelink, I.H, Boelens, J.J, Bredius, R.G.M, Egberts, A.C.G, Biering, M, Shaw, P, Nath, C.E, Hempel, G, Zwaveling, J, Danhof, M, Knibbe, C.A.J

Get full text

Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer by Pike-Overzet, K, Rodijk, M, Ng, Y-Y, Baert, M R M, Lagresle-Peyrou, C, Schambach, A, Zhang, F, Hoeben, R C, Hacein-Bey-Abina, S, Lankester, A C, Bredius, R G M, Driessen, G J A, Thrasher, A J, Baum, C, Cavazzana-Calvo, M, van Dongen, J J M, Staal, F J T

“…Severe combined immunodeficiency (SCID) patients with an inactivating mutation in recombination activation gene 1 ( RAG1 ) lack B and T cells due to the…”
Get full text

Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT) by Ansari, Marc, Huezo-Diaz, Patricia, Uppugunduri, Chakradhara Rao Satyanarayana, Nava, Tiago, Rezgui, Mohammed Aziz, Mlakar, Vid, Lesne, Laurence, Theoret, Yves, Chalandon, Yves, Dupuis, L Lee, Schechter, Tal, Bartelink, Imke H, Boelens, Jaap Jan, Bredius, R.G.M., Dalle, Jean-Hugues, Azarnoush, Saba, Sedlacek, Petr, Lewis, Victor A., Champagne, Martin, Peters, Christina, Bittencourt, Henrique, Krajinovic, Maja

“…Busulfan (BU) dose adjustment following therapeutic drug monitoring (TDM) contributes to better outcome of hematopoietic stem cell transplantation (HSCT). The…”
Get full text

Targeting to an Optimal AUC of Intravenous Busulfan Prevents Graft Failure In Transplantation In Children With Non-Malignant Diseases by Bartelink, I.H, Bredius, R.G.M, Bierings, M, Egeler, M, Lankester, A.C, Egberts, T.C.G, Zwaveling, J, Boelens, J.J

Get full text

194: Intravenous Busulfan in Children Prior to Haematological Stem Cell Transplantation, How Narrow is the Therapeutic Window? by Bartelink, I.H, Bredius, R.G.M, Egberts, T.C.G, Suttorp, M.M, Bierings, M, Knibbe, C, Zwaveling, J, Boelens, J.J

Get full text

Managing a dual role-experiences and coping strategies of parents donating haploidentical G-CSF mobilized peripheral blood stem cells to their children by van Walraven, S. M., Ball, L. M., Koopman, H. M., Switzer, G. E., Ropes-de Jong, C. M. H., de Jong, A., Bredius, R. G. M., Egeler, R. M.

“…Hematopoietic stem cell transplantation is an effective therapy for life‐threatening hematological diseases. Parents may be asked to donate hematopoietic stem…”
Get full text

IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD by Jol-van der Zijde, C M, Bredius, R G M, Jansen-Hoogendijk, A M, Raaijmakers, S, Egeler, R M, Lankester, A C, van Tol, M J D

“…Anti-thymocyte globulin (ATG), raised in rabbits, is frequently used in allogeneic hematopoietic SCT (HSCT), to prevent graft rejection and acute GVHD. In…”
Get full text

Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity by Vermont, C.L., Jol-van der Zijde, E.C.M., Hissink Muller, P., Ball, L.M., Bredius, R.G.M., Vossen, A.C., Lankester, A.C.

“…Background and aims Varicella zoster virus (VZV) reactivation following hematopoietic stem cell transplantation (HSCT) may cause significant morbidity and…”
Get full text

Antibodies to anti-thymocyte globulin in aplastic anemia patients have a negative impact on hematopoietic SCT by Jol-van der Zijde, C M, Bredius, R G M, Jansen-Hoogendijk, A M, Smiers, F J, Lankester, A C, van Tol, M J D

Get full text

Kinetics of active and total thymoglobulin in paediatric stem cell transplantation by Jol-van der Zijde, C.M, Jansen-Hoogendijk, A.M, Raaijmakers, S, Egeler, R, Lankester, A.C, Bredius, R.G.M, van Tol, M.J.D

“…Introduction: Polyclonal anti-thymocyte globulin (ATG, Imtix) is given prior to paediatric stem cell transplantation (SCT) to prevent rejection and…”
Get full text

Targeting to optimal busulfan exposure is associated with a low relapse rate and high acute-GvHD 2-4 rates in MDS and JMML patients by Bartelink, I.H, Bredius, R.G.M, Bierings, M, Knibbe, C.A.J, Egeler, M, Lankester, A.C, Egberts, A.C.G, Zwaveling, J, Boelens, J.J

“…Background: Busulfan combined with therapeutic drug monitoring and guided dosing is associated with higher event free survival (EFS) rates due to less…”
Get full text

Serotherapy in paediatric allogeneic stem cell transplantation: comparison of ATG and Campath-1H as part of conditioning by Jol-van der Zijde, C.M, Jansen-Hoogendijk, A.M, Egeler, R, Lankester, A.C, Bredius, R.G.M, van Tol, M.J.D

“…Polyclonal anti-thymocyte globulins (ATG) and monoclonal humanized Campath-1H (C1H) are regularly administered before allogeneic stem cell transplantation…”
Get full text

Targeting to an optimal AUC of intravenous busulfan prevents graft failure in transplantation in children with non-malignant diseases by Bartelink, I.H, Bredius, R.G.M, Belitser, S.V, Bierings, M, Knibbe, C.A.J, Egeler, M, Lankester, A.C, Egberts, A.C.G, Zwaveling, J, Boelens, J.J

“…Background: Busulfan combined with therapeutic drug monitoring guided dosing is associated with higher event free survival (EFS) rates due to less…”
Get full text

Mannose-binding lectin levels and infections in children after allogeneic hematopoietic SCT by Chaudhry, S H, Chaudhry, S, Jansen-Hoogendijk, A M, Jol van der Zijde, C M, van Tol, M J D, Roos, A, Bredius, R G M

“…Mannose-binding lectin (MBL) is an activator of the lectin pathway of the C′ system and hence an important component of the innate immune system. Although…”
Get full text

Abnormal liver enzymes two years after haematopoietic stem cell transplantation in children : prevalence and risk factors by BRESTERS, D, VAN GILS, I. C. M, DEKKER, F. W, LANKESTER, A. C, BREDIUS, R. G. M, SCHWEIZER, J. J

“…To establish the prevalence of elevated liver enzymes in children transplanted in a Dutch haematopoietic stem cell transplantation (HSCT) centre, we…”
Get full text

Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre by Vossen, J M, Donker, A E, Heemskerk, M B A, Lie, J L W T j, van Weel-Sipman, M H, Bredius, R G M, Bakker, J D J, Egeler, R M, Oudshoorn, M

“…The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available,…”
Get full text